The clinical trials comprised prospective reports of different statuses (i.e., recruiting, ongoing, completed, or terminated) performed on adult subjects (healthy or with PAH); the primary outcomes were safety or efficacy (inter alia 6MWD, hemodynamic parameters) associated with chronic exposure to an individual small-molecule protein kinase inhibitor [9,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125] (Figure 1). This evidence concerns the gene WEE1 and pulmonary arterial hypertension.